2016 American Transplant Congress
Preemptive CMV Prophylaxis in Renal Transplant Recipients Receiving Everolimus Immunosuppression Reduces Cytomegalovirus Infection.
Surgery - Renal Transplant Unit, Università Cattolica del Sacro Cuore, Rome, Italy.
Introduction.Aim of this study was to evaluate the efficacy and safety of preemptive prophylaxis of CMV infection in kidney transplant recipients (KTx) receiving polyclonal antibodies…2016 American Transplant Congress
Quantiferon-CMV Test, CMV-Specific ELISPOT and CMV-Dextramer Assays in Assessing the Risk of CMV Infection in Seropositive Kidney Transplant Recipients.
Human cytomegalovirus (CMV) infection is one of the primary opportunistic pathogens and is a leading cause of morbidity and mortality in kidney transplant recipients. Assessing…2016 American Transplant Congress
Reduced-Dose Cidofovir (CID) and CMV-Hyperimmune Globulin (CMVIg) for Ganciclovir-Resistant Cytomegalovirus: Effective and Kidney Friendly.
Houston Methodist Hospital, Houston, TX.
Ganciclovir resistant (GR) CMV is associated with an aggressive disease course and substantial morbidity. Furthermore, treatment options such as foscarnet and cidofovir are incredibly nephrotoxic.…2016 American Transplant Congress
Comparative Effectiveness of Cytomegalovirus Prevention Strategies in a Large Retrospective Cohort of Kidney Transplant Recipients.
Washington University School of Medicine, Saint Louis, MO.
Background: While CMV prevention strategies have been studied in carefully selected groups of patients enrolled in randomized trials, their comparative effectiveness in real-world settings is…2016 American Transplant Congress
Down-Regulated of Circulating miR-29b, miR-185 and NR_073415.2 in Post-Transplanted Patients with Cytomegalovirus Infection May Serve as Novel Biomarkers for Early Diagnosis.
Aims: Mortality of CMV infection in post-transplanted patients was quite high, which severely influencing the long-term survival of recipients. For giving them early treatment and…2016 American Transplant Congress
Risk Factors for the Development of CMV Viremia in a Cohort of Morbidly Obese Kidney Transplant Recipients Under Low Dose Valganciclovir Prophylaxis.
Background: The rate of Cytomegalovirus infections in kidney transplant recipients drastically diminished with the advent of oral ganciclovir and subsequently valganciclovir. However it continues to…2016 American Transplant Congress
Implementation of a Risk Stratified Approach for Prevention of Hepatitis B Reactivation Post Kidney Transplant.
A large percentage of patients with end stage renal disease are known to be Hepatitis B virus (HBV) positive. A 2015 consensus guideline on use…2016 American Transplant Congress
Development of a Sequencing-Based Cytomegalovirus UL55 Glycoprotein B (gB) Genotyping Assay.
Viracor-IBT Laboratories, Lee's Summit, MO.
Background: Human cytomegalovirus (hCMV) is an important agent of serious viral infection in the solid organ transplant and allogeneic hematopoietic stem cell transplant populations. Severe…2016 American Transplant Congress
CMV Monitoring Reduces Risk of Clinical Complications in Kidney Transplant Recipients.
MedStar Georgetown Transplant Institute, Georgetown University School of Medicine, Washington, DC.
Objective: Review the advantages of CMV viral load monitoring in preventing CMV associated complications in kidney transplant recipientsMethods: All individuals who underwent a kidney transplant…2016 American Transplant Congress
Hepatitis B Reactivation Among Non-Liver Solid Organ Transplant Recipients.
IntroductionThe purpose of this study was to evaluate the incidence of post-transplant hepatitis B (HBV) reactivation in patients who have previously cleared hepatitis B surface…